Mr. Pitts (for himself, Mr. Pallone, and Mr. Gene Green of Texas) introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned, Additional sponsor: Mrs. McMorris Rodgers, Reported from the Committee on Energy and Commerce with amendments, The Committee on the Judiciary discharged; committed to the Committee of the Whole House on the State of the Union and ordered to be printed
To amend the Controlled Substances Act with respect to drug scheduling recommendations by the Secretary of Health and Human Services, and with respect to registration of manufacturers and distributors seeking to conduct clinical testing.
Citations are generated automatically from bibliographic data
as a convenience and may not be complete or accurate.
Chicago
U.S. Congress. House. Improving Regulatory Transparency for New Medical Therapies Act. H.R. 639. 114th
Cong., 1st
sess., Reported in House March 16, 2015. https://www.govinfo.gov/app/details/BILLS-114hr639rh.
APA
Congress, House of Representatives (2015, March 16). Improving Regulatory Transparency for New Medical Therapies Act (H.R. 639 (RH)). Retrieved from https://www.govinfo.gov/app/details/BILLS-114hr639rh.
MLA
United States, Congress, House of Representatives. Improving Regulatory Transparency for New Medical Therapies Act. U.S. Government Publishing Office, https://www.govinfo.gov/app/details/BILLS-114hr639rh. 114th Congress, H.R. 639, Reported in House 16 Mar. 2015.
Bluebook
H.R.639 - 114th Congress (2015-2016): Improving Regulatory Transparency for New Medical Therapies Act, H.R.639, 114th Cong. (2015), https://www.govinfo.gov/app/details/BILLS-114hr639rh.
